Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Year: 2021
Type: conference-abstract
Source: Blood
Authors: Shaji Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina J. Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Maika Onishi, Grace Ku, Rajvineeth Kumar Pothacamury, Vasudha Sehgal, Abdullah A. Masud, Jeremy A. Ross, Edyta Dobkowska, Philippe Moreau
Institutions: Mayo Clinic, The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, University of Bologna, Hospital Universitari i Politècnic La Fe, University College London Hospitals NHS Foundation Trust, Duke Medical Center, São Germano Oncologia, Asklepios Klinik Altona, Asklepios Klinik St. Georg, Asklepios, Japanese Red Cross Medical Center, Seoul National University Hospital, Genentech, AbbVie (United States), Centre Hospitalier Universitaire de Nantes, Nantes Université
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3214046330